Bridging the gap between breakthrough science and real world therapies, biotech startup NanoZymeX is taking a significant step forward in transforming how rare genetic diseases are treated. The company has secured €160,000 in funding from Venture Kick to advance its innovative enzyme delivery platform, designed to overcome long standing limitations in enzyme replacement therapy.
Early Funding to Accelerate Innovation
The €160,000 investment provides NanoZymeX with critical early stage support as it transitions from academic research into a fully operational biotech company. This type of funding plays a vital role in enabling deep tech startups to move beyond the lab and begin building scalable solutions for real world medical challenges.
The company plans to use the capital to further develop its core technology, expand preclinical research, and prepare for future fundraising rounds. It also aims to lay the groundwork for scalable manufacturing and eventual clinical trials.
A New Approach to Enzyme Replacement Therapy
NanoZymeX is developing a platform based on lipid nanoparticles to enhance the delivery of therapeutic enzymes into cells. Enzyme replacement therapies are already used to treat several rare genetic disorders, but their effectiveness is often limited by delivery challenges.
In many cases, therapeutic proteins struggle to reach the cells and tissues where they are needed most. This is particularly problematic in diseases that affect organs such as skeletal muscle, where insufficient delivery reduces treatment impact. Additionally, repeated treatments can trigger immune responses, further limiting long term effectiveness.
NanoZymeX aims to address these issues by using lipid nanoparticles as carriers that transport enzymes directly into target cells and lysosomes. This approach improves intracellular delivery and increases the functional activity of the therapy.
Targeting Rare Diseases Like Pompe
One of the key focus areas for NanoZymeX is Pompe disease, a rare genetic disorder that affects the body’s ability to break down glycogen, leading to progressive muscle damage. Current treatments provide some benefit but often fall short due to limited delivery efficiency.
By enhancing how enzymes reach affected tissues, NanoZymeX’s platform has the potential to significantly improve outcomes for patients with Pompe disease and other similar conditions.
The company’s technology is also applicable to a broader category known as lysosomal storage disorders, a group of rare diseases that collectively represent a multibillion dollar therapeutic market.
Promising Early Results
Early preclinical studies have shown encouraging results, demonstrating strong delivery efficiency and improved enzyme activity in relevant tissues. These findings suggest that the platform could overcome key barriers that have historically limited the success of enzyme therapies.
Importantly, the technology is designed to be adaptable, meaning it can be applied to multiple diseases beyond its initial targets. This flexibility opens the door to a wide range of potential applications in rare disease treatment.
Building Partnerships for Future Growth
NanoZymeX plans to collaborate with pharmaceutical and biotechnology companies that are developing treatments for rare diseases. By integrating its delivery platform into existing and emerging therapies, the company aims to accelerate the development of next generation treatments.
Co founder Boris Sevarika emphasized the importance of early stage funding in enabling this progress. He noted that such support provides the flexibility needed for company building, business development, and preparing for larger investment rounds.
Moving Toward Clinical Impact
With its innovative approach and early validation, NanoZymeX is positioning itself to play a meaningful role in the future of rare disease treatment. The company’s next steps include advancing its technology through further studies and preparing for clinical development.
As the biotech industry continues to seek more effective and targeted therapies, NanoZymeX’s work highlights the potential of combining advanced delivery systems with existing treatments. By improving how therapies reach their destination, the company is aiming to unlock better outcomes for patients with some of the most challenging genetic conditions.
